Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of long-term safety of Tafinlar (dabrafenib) and/or Mekinist (trametinib)
jRCT2031210131Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of dabrafenib + trametinib and trametinib in cancer, sponsored by Novartis. Primary endpoint: Long-term safety (AEs/SAEs). Started Jul 2021; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2031210131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210131.